Key result
Most high-risk ASCVD patients lack high-intensity statins and fail to achieve LDL-C targets.
Why the study?
Prior studies identified incomplete uptake of ACC/AHA guideline-recommended statin therapy for secondary and high-risk primary ASCVD prevention in specific settings or populations.
Cross-Sectional
Yes
Answers are grounded in this paper and cite their sources.
Real-world data across seven US health systems reveals significant underutilization of high-intensity statin therapy and failure to meet LDL-C targets in high-risk primary and secondary ASCVD prevention cohorts.
Objective: The value of lipid lowering therapy (LLT) for prevention of atherosclerotic cardiovascular disease (ASCVD) is well understood. American College of Cardiology and American Heart Association guidelines recommend statin therapy for secondary and high-risk primary ASCVD prevention. Prior studies have identified incomplete uptake of these guidelines in specific practice settings or patient populations. Here we characterized real-world LLT prescribing relative to guideline recommendations across seven US health systems. Methods: Cross-sectional analyses of records from the PaTH Clinical Research Network focused on three cohorts: adults with ASCVD (ASCVD cohort), those aged 40-75 without ASCVD but with diabetes mellitus (DM cohort), and those not in either prior category but with a history of low-density lipoprotein (LDL-C) >190 mg/dl (LDL-C cohort). We describe patient characteristics, patterns of care, lipid values, and documented LLT within each cohort and variation between health systems. Results: > 160 mg/dl, 44 % were on statin therapy and 16 % on high-intensity statin therapy. There was significant variability in documented LLT between health systems. Conclusions: In this real-world descriptive study across multiple health systems for patients meeting criteria for secondary or high-risk primary ASCVD prevention, most patients had no documented high-intensity statin prescriptions and did not meet LDL-C targets. There was significant variability in care across health systems. Opportunities remain for improvement in guideline adherence to reduce ASCVD risk.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2025) conducted a cross-sectional in ASCVD, diabetes mellitus, or LDL-C >190 mg/dl. Lipid-lowering therapy was evaluated on Statin therapy prescription. Among patients meeting criteria for secondary or high-risk primary ASCVD prevention, only 44% were on statin therapy and 16% on high-intensity statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: